Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply
Aliment Pharmacol Ther
.
2018 Aug;48(3):388-389.
doi: 10.1111/apt.14855.
Authors
U Mahadevan
1
,
S Vermeire
2
,
K Lasch
3
,
B Abhyankar
4
,
F Bhayat
3
,
A Blake
5
,
M Dubinsky
6
Affiliations
1
Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
2
University Hospital Gasthuisberg, Leuven, Belgium.
3
Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
4
Formerly of Takeda Development Centre Europe Ltd, London, UK.
5
Takeda Development Centre Europe Ltd, London, UK.
6
Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
PMID:
29998501
DOI:
10.1111/apt.14855
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Female
Humans
Inflammatory Bowel Diseases*
Pregnancy
Substances
Antibodies, Monoclonal, Humanized
vedolizumab